• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Real-time monitoring of respiratory virus-associated hospitalizations: Trends from October 2019 through August 2024

Real-time monitoring of respiratory virus-associated hospitalizations: Trends from October 2019 through August 2024

by Truveta staff | Sep 19, 2024 | Research

Overall, the rate of hospitalizations associated with respiratory viruses remained stable throughout August 2024, with no change compared to July 2024. For infants and children aged 0-4 years old, respiratory virus-associated hospitalizations increased significantly...
Real-time monitoring of viral gastroenteritis: August 2024

Real-time monitoring of viral gastroenteritis: August 2024

by Truveta staff | Sep 11, 2024 | Research

The overall trends of hospitalizations associated with viral gastroenteritis – norovirus and rotavirus – show a steady decrease over the last few months, leading to a rate of 0.04% in August 2024 in the overall population. However, we see first indicators that the...
Truveta and the University of Washington’s CHOICE Institute partner to advance health economics and outcomes research

Truveta and the University of Washington’s CHOICE Institute partner to advance health economics and outcomes research

by Truveta News | Sep 4, 2024 | News

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy has partnered with Truveta to use its electronic health record (EHR) data to drive comparative, cost-effectiveness, and outcomes research....
ISPE 2024: Exploring the impact of removing race as a diagnostic factor for chronic kidney disease: Time to potassium-lowering drugs

ISPE 2024: Exploring the impact of removing race as a diagnostic factor for chronic kidney disease: Time to potassium-lowering drugs

by Truveta Research | Aug 23, 2024 | Research, Research Insights

Authors: Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
Trends in testing and diagnosis of peripheral vascular disease in the US

Trends in testing and diagnosis of peripheral vascular disease in the US

by Truveta Research | Jul 25, 2024 | Research, Research Insights

The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first time and had a diagnosis of peripheral vascular disease/peripheral artery disease...
« Older Entries
Next Entries »

Share this


Recent posts

  • Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
  • Top 5 takeaways from Truveta Symposium 2025
  • Women’s health: Pain medication remains rare for women receiving IUDs

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Get started

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Interested in learning more?